The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

Overview of attention for article published in Molecular Cancer, February 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

news: 1 news outlet
twitter: 7 tweeters

reddit: 1 Redditor

Citations

dimensions_citation: 82 Dimensions

Readers on

mendeley: 131 Mendeley

Summary News Twitter Reddit Dimensions citations

So far, Altmetric has seen 7 tweets from 7 users, with an upper bound of 6,691 followers.

RT @4baseCare: The efficacy of Tx is mostly guided by potency & the selectivity of a drug. Crizotinib a USFDA approved, ATP-competitive tar…

15 Feb 2022

Reply Retweet Favourite

The first-ever USFDA approved Targeted therapy for ALK-rearranged NSCLCs - Crizotinib. It has a good response over the conventional chemotherapy regime. @ALKLungCancer @LUNGevity

15 Feb 2022

Reply Retweet Favourite

RT @4baseCare: The efficacy of Tx is mostly guided by potency & the selectivity of a drug. Crizotinib a USFDA approved, ATP-competitive tar…

15 Feb 2022

Reply Retweet Favourite

RT @4baseCare: The efficacy of Tx is mostly guided by potency & the selectivity of a drug. Crizotinib a USFDA approved, ATP-competitive tar…

15 Feb 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 3 additional tweets.